MAXONA Pharmaceuticals has submitted an IND application seeking approval from the US FDA for its lead compound, MAX-001, to treat acute pain.

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...